SMBA1

Research use only, not for human use.

A potent, and selective Bax agonist (Ki=43.3 nM) that induces conformational changes in Bax by blocking S184 phosphorylation.

A potent, and selective Bax agonist (Ki=43.3 nM) that induces conformational changes in Bax by blocking S184 phosphorylation; shows no affinity for other Bcl2 family members, including Bcl2, Bcl-XL, Mcl-1, Bcl-w, Bfl-1/A1, Bid or Bak; facilitates Bax insertion into mitochondrial membranes and forming Bax oligomers, leads to cytochrome c release and apoptosis in human lung cancer cells; potently suppresses lung tumour growth via apoptosis by selectively activating Bax in vivo without significant normal tissue toxicity.

Western Blot Analysis Cell Line:A549 cells Concentration:0, 0.1, 1, 5, 10 μM Incubation Time:24 h Result:Increased the Bax expression in a dose-dependent manner

Animal Model:6-week-old male Nu/Nu mice (A549 lung cancer xenografts)Dosage:2, 10, 40, 60 mg/kg Administration:I.p.; once daily for 10 days Result:Supressed the tumor volume and increased levels of active caspase 3.

SMBA 1 | SMBA-1 | NSC 408730

Angiogenesis

Bcl-2

Bcl-2

——

——

906440-37-7

315.32

C20H13NO3

>98% (HPLC)

——

OC1=CC=CC=C1/C=C2C3=C(C4=C\2C=CC=C4)C=CC([N+]([O-])=O)=C3

(E)-2-((2-nitro-9H-fluoren-9-ylidene)methyl)phenol

(-20℃)

With Ice Pack

≥ 2 years